Kestra Advisory Services’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Kestra Advisory Services’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,161	Closed	-$563K	–	2221
2023 Q1	$563K	Sell	5,161 -26,802	-84%	-$2.96M	0.01%	1215
2022 Q4	$3.64M	Sell	31,963 -34,654	-52%	-$2.88M	0.03%	532
2022 Q3	$4.12M	Buy	66,617 +26,739	+67%	+$1.87M	0.04%	430
2022 Q2	$3.18M	Buy	39,878 +7,252	+22%	+$687K	0.03%	498
2022 Q1	$3.43M	Buy	32,626 +2,614	+9%	+$255K	0.04%	487
2021 Q4	$3.23M	Buy	30,012 +6,595	+28%	+$719K	0.03%	517
2021 Q3	$2.56M	Buy	23,417 +3,042	+15%	+$316K	0.03%	612
2021 Q2	$1.91M	Buy	20,375 +3,919	+24%	+$361K	0.02%	670
2021 Q1	$1.51M	Sell	16,456 -26,306	-62%	-$2.22M	0.02%	693
2020 Q4	$3.09M	Buy	42,762 +31,235	+271%	+$2.32M	0.04%	458
2020 Q3	$895K	Buy	+11,527	New	+$793K	0.02%	664

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Kestra Advisory Services's HZNP Position: Q2 2023 in Review

Kestra Advisory Services sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 5,161 shares — an estimated $563K sold.

Kestra Advisory Services first reported a position in HZNP in Q3 2020 and held it in 11 quarters. The position peaked at $4.12M in Q3 2022. 519 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

Kestra Advisory Services reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
Kestra Advisory Services sold 5,161 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $563K.
Kestra Advisory Services first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2020 and held it in 11 quarters.
Kestra Advisory Services's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $4.12M in Q3 2022.
519 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on Kestra Advisory Services's 13F filing for Q2 2023, filed 11 Aug 2023.